A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs FE 201836 (Primary) ; Desmopressin
- Indications Nocturia
- Focus Therapeutic Use
- Acronyms DAWN
- Sponsors Ferring Pharmaceuticals
- 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Aug 2017 Status changed from not yet recruiting to recruiting.
- 05 Jul 2017 New trial record